{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:02Z","timestamp":1791593822978,"version":"4.3.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is a severe acute autoimmune neuropathy with limited established therapeutic options. Efgartigimod, a human IgG antibody Fc fragment, can increase IgG degradation, which thus may be a promising therapeutic medicine for GBS. The aims of this study were to evaluate the clinical effectiveness and safety of efgartigimod in GBS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted on GBS patients at the first affiliated hospital of Zhengzhou university and Nanyang central hospital from February 2024 to June 2025. The medical records of patients received IVIg, efgartigimod, or IVIg sequential efgartigimod (ISE) were reviewed. Disease severity was evaluated using GBS disability score (GBS-DS) and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score at baseline, week1, week2, week3, week4, and the final follow-up. The primary outcome was the proportion of good improvement, defined as a reduction of at least 2 points in the GBS-DS score compared to the baseline. All adverse events occurred during the treatment period were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>52 patients were enrolled and received IVIg (n=20), efgartigimod (n=16), or ISE (n=16). Good improvement was higher in the efgartigimod group than IVIg group both at week 2 (37.5% vs. 0%, p&amp;lt;0.01) and the final visit (81.3% vs. 40.0%, p=0.02). Throughout follow-up, the proportion with GBS-DS \u22641 in the efgartigimod group was consistently higher compared to the other two groups. Although not statistically significant, the mean time to reach GBS-DS \u22641 was shorter in the efgartigimod group (2.6\u00b1 1.2 weeks) compared to the IVIg (3.1 \u00b1 1.1 weeks), In the ISE group, the average time to achieve GBS-DS \u2264 1 was 2.8 \u00b1 1.2 weeks. Regarding safety, the incidence of treatment-related adverse events (TEAEs) was lower in the efgartigimod group18.8% (3\/16) than in the IVIg50.0% (10\/20) and ISE 43.8% (7\/16) groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the preliminary finding, the retrospective real-world data suggesting a potential signal of benefit for efgartigimod in GBS, with no new safety concerns identified. However, this study cannot establish comparative efficacy given the methodological limitations, and large-scale well-controlled head-to-head trials remain imperative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1823319","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:30:45Z","timestamp":1781843445000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes and safety of efgartigimod in Guillain\u2013Barr\u00e9 syndrome: a retrospective observation study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongli","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanyang Central Hospital","place":["Nanyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"71","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00414-3","article-title":"Guillain-Barr\u00e9 syndrome outbreak in Pune: a health emergency","volume":"405","author":"Banerjee","year":"2025","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Nobuhiro","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16346","article-title":"Guillain\u2010Barr\u00e9 syndrome: History, pathogenesis, treatment, and future directions","volume":"31","author":"Hughes","year":"2024","journal-title":"Eur J Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41572-024-00580-4","article-title":"Guillain-Barr\u00e9 syndrome","volume":"10","author":"Leonhard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"B7","article-title":"Chinese guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome 2024","volume":"57","year":"2024","journal-title":"Chin J Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13613-020-00742-z","article-title":"Early mechanical ventilation in patients with Guillain-Barr\u00e9 syndrome at high risk of respiratory failure: a randomized trial","volume":"10","author":"Melone","year":"2020","journal-title":"Ann Intensive Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57066","article-title":"Treatment efficacy of plasmapheresis versus intravenous immunoglobulin in Guillain-Barr\u00e9 Syndrome management: A systematic review","volume":"16","author":"Savithri Nandeesha","year":"2024","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250336","article-title":"Expanding our understanding of Guillain\u2013Barr\u00e9 syndrome: Recent advances and clinical implications","volume":"54","author":"Ripellino","year":"2024","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13613-025-01464-w","article-title":"Critical insights for intensivists on Guillain-Barr\u00e9 syndrome","volume":"15","author":"Weiss","year":"2025","journal-title":"Ann Intensive Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000040700","article-title":"Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report","volume":"103","author":"Zhou","year":"2024","journal-title":"Medicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","article-title":"Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review","volume":"46","author":"Xu","year":"2025","journal-title":"Neurol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of Guillain\u2013Barr\u00e9 syndrome: a case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s13023-025-04060-0","article-title":"Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"20","author":"Zhang","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/17562864261419026","article-title":"Efgartigimod for Guillain\u2013Barr\u00e9 syndrome: a retrospective analysis of efficacy and safety","volume":"19","author":"Bi","year":"2026","journal-title":"Ther Adv Neurol Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1186\/s12967-024-05704-8","article-title":"Explore genetic susceptibility association between viral infections and Guillain-Barr\u00e9 syndrome risk using two-sample Mendelian randomization","volume":"22","author":"Kong","year":"2024","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1456663","article-title":"Causal effects of systemic inflammatory proteins on Guillain-Barre Syndrome: insights from genome-wide Mendelian randomization, single-cell RNA sequencing analysis, and network pharmacology","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001798.pub3","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"2017","author":"Chevret","year":"2017","journal-title":"Cochrane Database Systematic Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000235","article-title":"Immunoglobulin treatment in neuromuscular medicine","volume":"20","author":"Burakgazi","year":"2019","journal-title":"J Clin Neyromuscul Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00730","article-title":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study","volume":"22","author":"Guo","year":"2025","journal-title":"Neurotherapeutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:28:38Z","timestamp":1783016918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1823319"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823319","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1823319"}}